Dow Jones 10284.83 -29.17 9:10 am PST, May 04, 2004  NASDAQ 1937.79 -0.93 For info, visit access.smallcapnetwork.com S & P 500 1114.71 -2.78 To be removed, please click here Russell 2000 565.46 -0.02 VOLUME 04: ISSUE 34  Feature: BioCurex - Japan test results, Impressive. Tuesday morning, BioCurex (BOCX.PK) released data (release shown below) from an independent evaluation of its Histo-RECAF? tissue biopsy cancer detection system. The independent study was conducted in Japan by Dr. Kazuhita Taketa, MD, Head of the Clinical Trial Center and Emeritus Professor, Okayama University and Dr. SoTsuboi, Shigei Medical Research Hospital. During the time that BOCX trades on the pink sheets, real-time quotes are available here: http://www.pinksheets.com/quote/quote.jsp?symbol=BOCX. The shares moved to the pink sheets on April 23rd  at just over $1.00. Recently, the stock has noted some decent volumes and has perked back up to the $1.60-$1.70 level. As we noted in our last article--which would be a worthwhile read if you missed it--the company is moving ahead as fast as possible to reinstate its shares on the NASDAQ Bulletin Board.  For risk-oriented investors, and especially those who own BioCurex stock at much cheaper levels, we feel that strategic accumulation is warranted. As well, for those who sold stock at much higher prices, beginning to replace some of those shares at these levels would also be appropriate. While the number of samples tested in the Japan study was modest--45 samples of which 23 were stomach cancer tissue and 22 were normal-- the results are extremely impressive. Sensitivity (cancer detection rate) of the test was 82.6 percent while the specificity (lack of false positive/negative) was 95.5 percent. Most compelling is the fact that this test was conducted as an independent study and was funded exclusively by the group in Japan. Dr. Takeda, in a letter to BioCurex (available at the company website www.biocurex.com under news) states that he intends to write a paper on the findings and submit it to a peer-reviewed journal. Further, the results were accepted as a communication in the annual meeting of the International Society of Oncodevelopmental Biology and Medicine. Investors should take some notice that as these studies report, there is a consistency developing in the results. As we have noted before, these independent results from Japan for the detection of stomach cancer are in line with other studies for ovarian, breast and lung cancer, which have shown sensitivities of 90 percent-plus and specificities of 95 percent-plus. These figures are well in excess of any other 'competitive' tests available. In the case of breast cancer, the sensitivity is 100 percent. The progress of BioCurex is somewhat analogous to the building of a boat. Each 'plank' added, be it a study or a new research and development initiative, strengthens the ship and makes it ever more sea-worthy. Today's announcement represents a strong and significant plank in eventually moving the company from dry-dock to the open ocean.  While these may have been somewhat challenging times for BioCurex, the company has worked to keep investors informed and has stood steadfast as to the value and potential of its technology.  Our oft-stated feeling is that once BioCurex's technologies are commercialized--which we believe will begin in 2004--the way cancer is detected and treated could well be revolutionized. We will continue to follow, report and comment on this unique early-stage biotech.  It's just way too interesting to ignore. NOTE: Traders and interested others might want to check out www.mytrack.com. We are having a look at this online trading service, as it seems very robust and feature-rich with reasonable prices. And, we believe, as well as being a standard online trading company, investors can point and click trade pink sheet stocks as well as Canadian equities. We'll bring you more details as we unearth them. Or, if any of y'all have experience with mytrack.com , drop us a line.   PRESS RELEASE BioCurex Announces Validation of its Cancer Detection System by Research Centers And Hospitals In Japan RICHMOND, B.C., May 4, 2004 (BUSINESS WIRE) -- BioCurex Inc. (Pink Sheets: BOCX) announced today the results of an independent evaluation of the company's Histo-RECAF(TM) based cancer detection system in Japan. The work, which was started last year, involved Dr. Kazuhita Taketa, MD, Head of the Clinical Trial Center and Emeritus Professor, Okayama University and Dr. SoTsuboi, Shigei Medical Research Hospital. The study comprised 23 stomach cancer and 22 normal tissue samples. The Histo-RECAF(TM) test detected 82.6% of cancers with a specificity of 95.5%. Dr. Taketa, a well known scientist in the area of cancer markers wrote in his letter to Dr. Moro: "Thank you for providing us the very valuable antibodies for RECAF. They can be used as the most specific and sensitive markers of malignancy." Dr. Taketa added: "We are in the process of writing a paper and submitting these results for publication in a peer reviewed journal." The letter, which can be read in the News section of our web site, also states that the results were accepted as a communication in the annual meeting of the International Society of Oncodevelopmental Biology and Medicine. Dr. Moro stated: "I am extremely pleased with Dr. Taketa's results and also because they were obtained completely independently from us, in their own laboratories and using their own funding. "Our investors should feel reassured by this independent validation of our technology. This report will hopefully put any questions about our claims to rest and help us in the process of licensing our technologies. "We expect that as more results come to light, more and more laboratories will take an interest in this remarkable molecule and participate in the work necessary to broaden the range of its applications." Dr. Phil Gold, Director and Chairman of BioCurex's Scientific Advisory Board commented: "The data obtained by Dr. Taketa's group in Japan are most impressive. It is of interest that the results of the staining procedure are so close in both sensitivity and specificity to those previously obtained with the blood samples of cancer patients that have been studied. Obviously, more work is still required to allow for definitive conclusions, but this information is most exciting going forward." The tissue results from Dr. Taketa's group coincide with those obtained using BioCurex's blood test -- Serum-RECAF -- as outlined in previous press releases which reported 84% detection of stomach cancers, and over 90% sensitivity (with 95% specificity) for breast, ovarian and lung cancers. This consistency is a critical feature of effective and valuable biotechnology. A copy of Dr. Taketa's letter will be placed on the website News section. Each year, there are twenty-three thousand stomach cancers identified with 14,000 reported deaths in the USA alone. The incidence and mortality rates in China, the Koreas and Japan are 5-7 times higher. In Japan, stomach cancer is responsible for one out of four deaths by cancer. The high mortality rate is due to the late stages at which stomach cancer is detected. Early detection is the key to effective treatment. About BioCurex: Real-time Level II market quotes for BioCurex can be found at: http://www.pinksheets.com/quote/quote.jsp?symbol=BOCX.  BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section in our web site (www.biocurex.com). Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. SOURCE: BioCurex, Inc. BioCurex, Inc. Ricardo Moro, 604-207-9150   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Unsubscribe Here D I S C L A I M E R : The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month.  All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.